The unreasonable director-related transaction claims
59 It is convenient to begin with the unreasonable director-related transaction claims under s 588FDA of the Corporations Act.
60 The first transfer occurred on or about 10 May 2019 and the second transfer occurred on or about 9 June 2021. Those are accordingly the relevant dates for the purpose of identifying the applicable statutory provisions. Although it has since been amended, at both those times s 588FDA of the Corporations Act was relevantly in the following terms:
588FDA Unreasonable director-related transactions
(1) A transaction of a company is an unreasonable director-related transaction of the company if, and only if:
(a) the transaction is:
(i) a payment made by the company; or
(ii) a conveyance, transfer or other disposition by the company of property of the company; or
(iii) the issue of securities by the company; or
(iv) the incurring by the company of an obligation to make such a payment, disposition or issue; and
(b) the payment, disposition or issue is, or is to be, made to:
(i) a director of the company; or
(ii) a close associate of a director of the company; or
(iii) a person on behalf of, or for the benefit of, a person mentioned in subparagraph (i) or (ii); and
(c) it may be expected that a reasonable person in the company's circumstances would not have entered into the transaction, having regard to:
(i) the benefits (if any) to the company of entering into the transaction; and
(ii) the detriment to the company of entering into the transaction; and
(iii) the respective benefits to other parties to the transaction of entering into it; and
(iv) any other relevant matter.
The obligation referred to in subparagraph (a)(iv) may be a contingent obligation.
Note: Subparagraph (a)(iv) - This would include, for example, granting options over shares in the company.
(2) To avoid doubt, if:
(a) the transaction is a payment, disposition or issue; and
(b) the transaction is entered into for the purpose of meeting an obligation the company has incurred;
the test in paragraph (1)(c) applies to the transaction taking into account the circumstances as they exist at the time when the transaction is entered into (rather than as they existed at the time when the obligation was incurred).
(3) A transaction may be an unreasonable director-related transaction because of subsection (1):
(a) whether or not a creditor of the company is a party to the transaction; and
(b) even if the transaction is given effect to, or is required to be given effect to, because of an order of an Australian court or a direction by an agency.
61 At the relevant times, "close associate" of a director was defined in s 9 of the Corporations Act as meaning a relative of the director or a relative of a spouse of the director. "Benefit" was defined as including any benefit, whether by way of payment of cash or otherwise. Also, by s 2C of the Acts Interpretation Act 1901 (Cth), "person" in s 588FDA(1)(b)(iii) includes a company or corporation.
62 There can be no doubt that the transfers of the trade marks from WAUS to Watchman and then from Watchman to EW1892 amounted to the "transfer or other disposition … of property of the company" in each case within the meaning of s 588FDA(1)(a)(ii).
63 In each case, the transfer of the trade marks was effected by Mr Fourie as director of the transferor company to a company in which Mr Fourie was the sole shareholder. That raises the question whether an indirect benefit of that nature is a "benefit" to Mr Fourie within the meaning of s 588FDA(1)(b)(iii) referring back to sub-para (i). That is to say, was the disposition in each case a disposition made to the transferee "for the benefit of" Mr Fourie as director of the transferor?
64 There are some cases in the NSW Supreme Court that gave a narrow interpretation to the phrase "for the benefit of" so as to exclude an indirect, or derivative, benefit that the director of the transferor gets as a shareholder of the transferee company: Ziade Investments Pty Ltd (in liq) v Welcome Homes Real Estate Pty Ltd [2006] NSWSC 457; 57 ACSR 693 per Gzell J at [86]-[89] and Re Great Wall Resources Pty Ltd (in liq) [2013] NSWSC 354 per Brereton J at [46]. However, the Court of Appeal of the Supreme Court of Victoria took a broader view in Vasudevan v Becon Construction (Australia) Pty Ltd [2014] VSCA 14; 41 VR 445 at [19] and [26]-[31] per Nettle JA, Beach JA and McMillan AJA agreeing. The Court reasoned that a derivative benefit such as that of a shareholder is captured by the provision, but in that case there was in any event a direct benefit so the reasoning as to indirect benefit was obiter.
65 The approach in Vasudevan was followed by Rangiah J in Pearce v Gulmohar Pty Ltd [2017] FCA 660 at [381] and Gleeson J in Re IW4U Pty Ltd (in liq) [2021] NSWSC 40; 150 ACSR 146 at [85]. Williams J followed IW4U in Re Bryve Resources Pty Ltd [2022] NSWSC 647; 163 ACSR 310 at [94]. Halley J took a similarly wide view in Tang v Roths Holdings Australia Pty Ltd, AXL Financial Pty Ltd (in liq) [2023] FCA 492 at [39]. Not only am I not satisfied that the wider approach is clearly wrong, I am satisfied that it is correct. That is for the reasons given in Vasudevan and IW4U.
66 In the circumstances, s 588FDA(1)(b)(iii) is satisfied.
67 Turning now to s 588FDA(1)(c), it is to be observed that in respect of the first transfer WAUS received only $30,000 for the trade marks that were valued at nearly about $1.9 million. Mr Fourie said that the price of $30,000 for the disposition of the trade marks from WAUS to Watchman was an "arbitrary" figure - "we just picked an arbitrary figure … it could have been anything" (T134:25). No attempt was made by Mr Fourie to justify the figure as not being detrimental to WAUS and against its interests.
68 Mr Fourie explained that after the MBO a number of "serious liabilities" in the group became apparent. A "risk-averting strategy" was embarked on because of the "potential risk" of claims, particularly from the ATO, which included putting the "legacy companies" that had the liabilities "to one side" and starting "afresh" with a number of "clean companies". The legacy companies included WAUS. The strategy included safeguarding the assets, including the relevant trade marks. I infer that that is why the trade marks were transferred from WAUS to Watchman. (See T90:9-100:19.)
69 I should mention that Mr Fourie went to some lengths to show that the trade marks had been impaired in the books of WAUS and that there was justification for that impairment. That is, however, not to the point for present purposes because he accepted that Mr Giliberti's valuation of the trade marks at the relevant times (May 2019, June 2021 and the time of trial) was correct. He also accepted, as mentioned, that the consideration for the transfer to Watchman was arbitrary.
70 In the result, I am satisfied that, within the meaning of s 588FDA(1)(c), a reasonable person in WAUS's circumstances would not have entered into the transaction that transferred the trade marks from WAUS to Watchman - they were transferred away for a pittance to WAUS's evident substantial detriment. It was accordingly an unreasonable director-related transaction within the meaning of s 588FDA.
71 Turning now to the second transfer, Watchman disposed of the trade marks to EW1892 in return for a right to receive payments amounting to a total of $143,185 over seven years for the lease to EW1892 of unidentified physical assets. However, because the Asporo deal fell through, the deed of lease and security was never implemented and Watchman received no payments under the deed.
72 I am satisfied that the deal by which Watchman transferred the trade marks to EW1892 was substantially to Watchman's detriment because what it reasonably anticipated receiving was very substantially less than the value of the trade marks. There is also no compelling explanation of the commercial purpose of the transaction from the perspective of Watchman. The transfer is not a transaction that a reasonable person in Watchman's circumstances would have entered into. It is accordingly an unreasonable director-related transaction within the meaning of s 588FDA of the Corporations Act.
73 Mr Fourie's evidence, which I accept, is that each transaction was entered into as part of a larger series of transactions aimed at enhancing the interests of the group of companies as a whole. There is no suggestion in the evidence that the particular interests of the transferor company were separately considered on each occasion. There is also no reliance sought to be placed on s 187 of the Corporations Act which provides some protection to a director who purports to act in the interests of the holding company rather than the wholly-owned subsidiary of which they are the director provided that certain conditions are met. Not only is that provision not relied on, but the evidence does not allow me to be satisfied that the requisite conditions were met. It follows that Mr Fourie as director of the subsidiary was in respect of each transaction bound to act in the interests of the subsidiary and not only with an eye to the interests of the group as a whole. See Walker v Wimborne [1976] HCA 7; 137 CLR 1 at 6 and Equiticorp Finance Ltd (in liq) v Bank of New Zealand (1993) 32 NSWLR 50 at 148.
74 In the circumstances, both the first and second transfers were unreasonable director-related transactions within the meaning of s 588FDA. Under s 588FE(6A) such a transaction is voidable if it was entered into, or an act was done for the purpose of giving effect to it, during the four years ending on the relation-back day.
75 By item 1 of the table in s 91 of the Corporations Act, read with s 513C(a), the relation-back day for WAUS was the day that it entered administration, ie 8 July 2021. The transfer of the trade marks to Watchman in June 2019 was well within the stipulated four year period.
76 As mentioned, Watchman was wound up in insolvency by court order on 22 September 2023. That was pursuant to a proceeding filed on 14 July 2023 which is accordingly the relation-back day: s 91, item 14. The second transfer in June 2021 was therefore well within the preceding stipulated period of four years.
77 The result is that both the transfers are voidable transactions.
78 Section 588FF provides for what orders can be made in relation to voidable transactions. They include orders for the transfer to "the company" (ie WAUS in this case in respect of the first transaction and Watchman in respect of the second) of property that the company has transferred under the transaction and orders for the payment of money in an amount that, in the court's opinion, fairly represents some or all of the benefits that the person has received because of the transaction.
79 Those provisions justify orders for the transfer of the trade marks from EW1892 back to WAUS (ie the plaintiff as liquidator of WAUS) and, failing that, for the payment of the value of the trade marks by Mr Fourie who is the person who has, through his shareholding in EW1892, received the benefit of the trade marks: Fitz Jersey Pty Ltd v Atlas Construction Group Pty Ltd (in liq) [2022] NSWSC 394.
80 The liquidator in this case seeks declarations and orders for the transfer of the trade marks to WAUS and for liberty to apply for an order for compensation in the event that the trade marks are not transferred to WAUS. Such orders are supported by the evidence, as explained.
81 In light of my conclusions on the unreasonable director-related transactions claims, the alternative claims can be dealt with relatively briefly.